vs
ExlService Holdings, Inc.（EXLS）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $542.6M、ExlService Holdings, Inc.の約1.5倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 11.1%、差は35.0%）。ExlService Holdings, Inc.の前年同期比売上増加率が高い（12.7% vs 7.4%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $106.5M）。過去8四半期でExlService Holdings, Inc.の売上複合成長率が高い（11.5% vs 8.0%）
ExlService Holdings Inc.は保険、ヘルスケア、銀行・金融サービス、メディア、小売などの業界を対象に分析・デジタルソリューションを提供するグローバル企業で、本社はニューヨークに所在し、米国、欧州、アジア、中南米、オーストラリア、南アフリカなど世界各地に5万4000人以上の専門スタッフを擁しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
EXLS vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $542.6M | $790.2M |
| 純利益 | $60.2M | $364.3M |
| 粗利率 | 38.6% | 86.9% |
| 営業利益率 | 14.4% | 45.1% |
| 純利益率 | 11.1% | 46.1% |
| 売上前年比 | 12.7% | 7.4% |
| 純利益前年比 | 18.9% | 20.9% |
| EPS（希薄化後） | $0.38 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $542.6M | $790.2M | ||
| Q3 25 | $529.6M | $799.5M | ||
| Q2 25 | $514.5M | $798.6M | ||
| Q1 25 | $501.0M | $794.4M | ||
| Q4 24 | $481.4M | $735.9M | ||
| Q3 24 | $472.1M | $748.9M | ||
| Q2 24 | $448.4M | $714.9M | ||
| Q1 24 | $436.5M | $677.7M |
| Q4 25 | $60.2M | $364.3M | ||
| Q3 25 | $58.2M | $338.7M | ||
| Q2 25 | $66.1M | $309.5M | ||
| Q1 25 | $66.6M | $322.2M | ||
| Q4 24 | $50.7M | $301.3M | ||
| Q3 24 | $53.0M | $309.1M | ||
| Q2 24 | $45.8M | $278.1M | ||
| Q1 24 | $48.8M | $306.6M |
| Q4 25 | 38.6% | 86.9% | ||
| Q3 25 | 38.5% | 87.4% | ||
| Q2 25 | 37.7% | 89.0% | ||
| Q1 25 | 38.6% | 88.4% | ||
| Q4 24 | 38.1% | 89.7% | ||
| Q3 24 | 37.8% | 88.9% | ||
| Q2 24 | 37.1% | 89.1% | ||
| Q1 24 | 37.4% | 89.2% |
| Q4 25 | 14.4% | 45.1% | ||
| Q3 25 | 14.4% | 48.6% | ||
| Q2 25 | 15.8% | 45.6% | ||
| Q1 25 | 15.7% | 48.2% | ||
| Q4 24 | 14.8% | 48.6% | ||
| Q3 24 | 14.7% | 45.8% | ||
| Q2 24 | 13.7% | 44.7% | ||
| Q1 24 | 14.1% | 52.6% |
| Q4 25 | 11.1% | 46.1% | ||
| Q3 25 | 11.0% | 42.4% | ||
| Q2 25 | 12.8% | 38.8% | ||
| Q1 25 | 13.3% | 40.6% | ||
| Q4 24 | 10.5% | 40.9% | ||
| Q3 24 | 11.2% | 41.3% | ||
| Q2 24 | 10.2% | 38.9% | ||
| Q1 24 | 11.2% | 45.2% |
| Q4 25 | $0.38 | $7.66 | ||
| Q3 25 | $0.36 | $7.16 | ||
| Q2 25 | $0.40 | $6.41 | ||
| Q1 25 | $0.40 | $6.63 | ||
| Q4 24 | $0.31 | $6.23 | ||
| Q3 24 | $0.33 | $6.39 | ||
| Q2 24 | $0.28 | $5.85 | ||
| Q1 24 | $0.29 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $328.4M | $2.9B |
| 総負債低いほど良い | $298.6M | — |
| 株主資本純資産 | $912.7M | $7.1B |
| 総資産 | $1.7B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.33× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $328.4M | $2.9B | ||
| Q3 25 | $390.1M | $2.8B | ||
| Q2 25 | $353.3M | $3.0B | ||
| Q1 25 | $331.4M | $3.3B | ||
| Q4 24 | $340.6M | $3.3B | ||
| Q3 24 | $325.8M | $3.3B | ||
| Q2 24 | $276.1M | $3.0B | ||
| Q1 24 | $246.2M | $2.7B |
| Q4 25 | $298.6M | — | ||
| Q3 25 | $354.8M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $307.3M | — | ||
| Q4 24 | $288.5M | — | ||
| Q3 24 | $344.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $912.7M | $7.1B | ||
| Q3 25 | $952.4M | $6.6B | ||
| Q2 25 | $1.1B | $7.2B | ||
| Q1 25 | $1.0B | $6.8B | ||
| Q4 24 | $929.9M | $6.4B | ||
| Q3 24 | $907.6M | $6.1B | ||
| Q2 24 | $852.6M | $5.7B | ||
| Q1 24 | $803.3M | $5.3B |
| Q4 25 | $1.7B | $7.9B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.9B | ||
| Q1 25 | $1.7B | $7.7B | ||
| Q4 24 | $1.6B | $7.4B | ||
| Q3 24 | $1.6B | $7.1B | ||
| Q2 24 | $1.5B | $6.7B | ||
| Q1 24 | $1.4B | $6.5B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $117.4M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $106.5M | $173.3M |
| FCFマージンFCF / 売上 | 19.6% | 21.9% |
| 設備投資強度設備投資 / 売上 | 2.0% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.95× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $298.1M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $117.4M | $346.2M | ||
| Q3 25 | $120.7M | $562.1M | ||
| Q2 25 | $109.4M | $191.7M | ||
| Q1 25 | $3.2M | $461.2M | ||
| Q4 24 | $105.3M | $341.2M | ||
| Q3 24 | $110.1M | $377.2M | ||
| Q2 24 | $74.9M | $232.2M | ||
| Q1 24 | $-21.9M | $376.5M |
| Q4 25 | $106.5M | $173.3M | ||
| Q3 25 | $106.4M | $351.6M | ||
| Q2 25 | $95.0M | $129.5M | ||
| Q1 25 | $-9.7M | $386.3M | ||
| Q4 24 | $95.3M | $254.5M | ||
| Q3 24 | $97.3M | $300.7M | ||
| Q2 24 | $62.8M | $187.1M | ||
| Q1 24 | $-33.1M | $338.3M |
| Q4 25 | 19.6% | 21.9% | ||
| Q3 25 | 20.1% | 44.0% | ||
| Q2 25 | 18.5% | 16.2% | ||
| Q1 25 | -1.9% | 48.6% | ||
| Q4 24 | 19.8% | 34.6% | ||
| Q3 24 | 20.6% | 40.2% | ||
| Q2 24 | 14.0% | 26.2% | ||
| Q1 24 | -7.6% | 49.9% |
| Q4 25 | 2.0% | 21.9% | ||
| Q3 25 | 2.7% | 26.3% | ||
| Q2 25 | 2.8% | 7.8% | ||
| Q1 25 | 2.6% | 9.4% | ||
| Q4 24 | 2.1% | 11.8% | ||
| Q3 24 | 2.7% | 10.2% | ||
| Q2 24 | 2.7% | 6.3% | ||
| Q1 24 | 2.6% | 5.6% |
| Q4 25 | 1.95× | 0.95× | ||
| Q3 25 | 2.08× | 1.66× | ||
| Q2 25 | 1.66× | 0.62× | ||
| Q1 25 | 0.05× | 1.43× | ||
| Q4 24 | 2.08× | 1.13× | ||
| Q3 24 | 2.08× | 1.22× | ||
| Q2 24 | 1.63× | 0.83× | ||
| Q1 24 | -0.45× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
